Relay Therapeutics Quarterly Balance Sheet
NASDAQ: RLAYHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Relay Therapeutics financial position
As of Jun 30, 2026, Relay Therapeutics reported total assets of $967.5 million, up 32.7% from a year earlier against total liabilities of $77.4 million. Shareholders' equity stood at $890.0 million, or 92.0% of assets. The company held $121.2 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 18.27, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Relay Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 121.19M | 204.59M | 84.02M | 91.56M | 113.94M | 93.54M | 124.29M | 152.36M | 134.13M | 152.87M | 143.74M | 151.33M |
| Receivables | — | — | — | — | — | — | — | — | — | — | — | 211.00K |
| Total Current Assets | 928.08M | 658.46M | 578.28M | 624.01M | 680.39M | 739.66M | 809.20M | 865.13M | 704.27M | 770.10M | 770.10M | 831.80M |
| Property, Plant & Equipment | 862.00K | 1.22M | 1.73M | 2.36M | 3.46M | 5.15M | 5.91M | 7.21M | 8.35M | 9.88M | 10.90M | 10.70M |
| Intangible Assets | — | — | — | — | — | — | — | 2.30M | 2.30M | 2.30M | 2.30M | 2.30M |
| Total Assets | 967.46M | 699.61M | 621.33M | 670.00M | 728.84M | 799.36M | 871.30M | 930.12M | 772.55M | 841.44M | 843.98M | 906.96M |
| Accounts Payable | 11.46M | 4.10M | 7.71M | 2.75M | 5.18M | 8.45M | 14.10M | 6.87M | 11.17M | 7.97M | 9.21M | 13.35M |
| Total Current Liabilities | 50.80M | 29.75M | 25.58M | 32.60M | 32.52M | 37.05M | 50.73M | 46.97M | 45.04M | 37.14M | 30.27M | 50.75M |
| Total Liabilities | 77.45M | 57.43M | 54.27M | 62.29M | 63.18M | 78.28M | 93.50M | 91.25M | 90.81M | 95.68M | 91.98M | 128.59M |
| Shareholders' Equity | 890.01M | 642.18M | 567.06M | 607.71M | 665.66M | 721.08M | 777.79M | 838.86M | 681.74M | 745.76M | 752.00M | 778.37M |
| Retained Earnings | -2.17B | -2.09B | -2.01B | -1.96B | -1.89B | -1.82B | -1.74B | -1.66B | -1.57B | -1.48B | -1.40B | -1.32B |
| Net Cash (Debt) | 121.19M | 204.59M | 84.02M | 91.56M | 113.94M | 93.54M | 124.29M | 152.36M | 134.13M | 152.87M | 143.74M | 151.33M |
| Shares Outstanding | 218.53M | 189.21M | 173.87M | 172.63M | 171.69M | 170.48M | 167.76M | 166.89M | 133.32M | 132.30M | 127.46M | 123.16M |
This table shows 12 quarterly periods of Relay Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, receivables, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow RLAY's reporting calendar. What is a balance sheet?